REG - EKF Diagnostics Hldg - Purchase of Own Shares

EKF Diagnostics HoldingsAnnouncement

08/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220408:nRSH7073Ha&default-theme=true

RNS Number : 7073H  EKF Diagnostics Holdings PLC  08 April 2022

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Purchase of Own Shares

Further to the confirmation of its intention to implement a share buyback
programme, as set out in its announcement on 29 March 2022, the Company
announces that it has purchased a total of 500,000 of its ordinary shares at a
price of 40.08 pence per share. The ordinary shares purchased will be held in
treasury.

 

Aggregated information

 

 Date of purchase                     7 April 2022
 Number of ordinary shares purchased  500,000
 Highest price paid per share         40.5
 Lowest price paid per share          39.6
 Volume weighted average price paid   40.08

 

 

Transaction details

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation) (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018), a detailed breakdown of individual
trades is available below:

 

 

 Number of ordinary shares purchased  Transaction price (GBp)  Time of transaction  Trading venue
 200,000                              39.6                     15:37:54             AIMX
 150,000                              40.3                     13:35:08             AIMX
 150,000                              40.5                     09:44:57             AIMX

 

Total voting rights

 

Following the purchase, the Company's total issued share capital will consist
of 463,930,564 ordinary shares of 1 pence each ("Ordinary Shares") each
carrying one voting right, of which 8,800,000 Ordinary Shares are held in
treasury. Therefore, the total number of Ordinary Shares carrying voting
rights will be 455,130,564. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 Enquiries:

EKF Diagnostics Holdings plc                                 www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)

 Mike Salter, CEO                                             via Walbrook PR

 Marc Davies, CFO

 Singer Capital Markets (Nominated Adviser and Joint Broker)  +44 (0)20 7496 3000

 Aubrey Powell / George Tzimas / Tom Salvesen

 Investec Bank plc (Joint Broker)                             +44 (0)20 7597 4000

 Gary Clarence / Daniel Adams

 Walbrook PR Limited                                          +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)

 Paul McManus / Lianne Applegarth                             Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

 About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
 (http://www.ekfdiagnostics.com) )

 EKF is a leading global diagnostics business with custom manufacturing
 facilities across sites in the US, UK and Europe for a variety of life science
 products. EKF is focussed on the following areas:

Point-of-Care             Providing a portfolio Point-of-Care analysers and consumables, particularly
              for use in the area of Hematology and Diabetes, for use in hospital and
              research laboratories, doctor's offices, blood banks and for in-field anaemia
              screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit,
              HbA1c, glucose and lactate analysers in regular use across more than 100
              countries.

 Central Laboratory        Clinical chemistry, Small lab analysers, Centrifuges

              Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum
              Protein, Nitro-tab, Procalcitonin

 Life Sciences             Enzyme fermentation, Custom products and Bulk fermentation

 Contract Manufacturing    Bulk formulation, Sample collection kits, Private labelling, Molecular and
              forensic kits

 Laboratory Services       In September 2021, EKF completed the acquisition of Advanced Diagnostic
              Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified
              under the Clinical Laboratory Improvement Amendments ("CLIA") for high
              complexity testing. The laboratory provides testing for a variety of clinical,
              forensic and microbiological sample types using a range of analytical
              techniques. This acquisition positions EKF as a leading 'one stop' provider of
              diagnostic products and services from sample collection to results.

 

 In May 2021, EKF announced its strategy for delivering growth to 2024 and
 beyond, and continuing to deliver shareholder value. The strategy for growth
 can be summarised as:

 ·      continuing innovation in products and services in Point-of-Care,
 Central Laboratory and Life Sciences leveraging new and existing routes to
 market and relationships;

 ·      investment in expanded production and kitting capabilities to
 offer a suite of diagnostic Contract Manufacturing solutions to third party
 businesses;

 ·      expansion of CLIA Laboratories Testing offering building on the
 acquired capabilities in ADL Health; and

 ·      identify complementary earnings-enhancing acquisitions with key
 strategic value.

 EKF will also continue to generate enhanced shareholder value through:

 ·      a progressive dividend policy; and

 ·      its agreement with Mount Sinai Innovation Partners ("MSIP"),
 which allows us advanced access to innovative commercial opportunities and
 where we can build on the ongoing successes of Renalytix plc, Verici Dx plc
 and Trellus Health plc.

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

EKF is a leading global diagnostics business with custom manufacturing
facilities across sites in the US, UK and Europe for a variety of life science
products. EKF is focussed on the following areas:

 

 Point-of-Care             Providing a portfolio Point-of-Care analysers and consumables, particularly
                           for use in the area of Hematology and Diabetes, for use in hospital and
                           research laboratories, doctor's offices, blood banks and for in-field anaemia
                           screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit,
                           HbA1c, glucose and lactate analysers in regular use across more than 100
                           countries.

 Central Laboratory        Clinical chemistry, Small lab analysers, Centrifuges

                           Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum
                           Protein, Nitro-tab, Procalcitonin

 Life Sciences             Enzyme fermentation, Custom products and Bulk fermentation

 Contract Manufacturing    Bulk formulation, Sample collection kits, Private labelling, Molecular and
                           forensic kits

 Laboratory Services       In September 2021, EKF completed the acquisition of Advanced Diagnostic
                           Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified
                           under the Clinical Laboratory Improvement Amendments ("CLIA") for high
                           complexity testing. The laboratory provides testing for a variety of clinical,
                           forensic and microbiological sample types using a range of analytical
                           techniques. This acquisition positions EKF as a leading 'one stop' provider of
                           diagnostic products and services from sample collection to results.

 

In May 2021, EKF announced its strategy for delivering growth to 2024 and
beyond, and continuing to deliver shareholder value. The strategy for growth
can be summarised as:

 

·      continuing innovation in products and services in Point-of-Care,
Central Laboratory and Life Sciences leveraging new and existing routes to
market and relationships;

·      investment in expanded production and kitting capabilities to
offer a suite of diagnostic Contract Manufacturing solutions to third party
businesses;

·      expansion of CLIA Laboratories Testing offering building on the
acquired capabilities in ADL Health; and

·      identify complementary earnings-enhancing acquisitions with key
strategic value.

 

EKF will also continue to generate enhanced shareholder value through:

 

·      a progressive dividend policy; and

·      its agreement with Mount Sinai Innovation Partners ("MSIP"),
which allows us advanced access to innovative commercial opportunities and
where we can build on the ongoing successes of Renalytix plc, Verici Dx plc
and Trellus Health plc.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSSSAFIWEESEIL